Anti-genes: siRNA, ribozymes and antisense

Current Pharmaceutical Biotechnology

Volumn 5, Issue 5, 2004, Pages 415-420

  Scanlon, Kevin J ^a  

^a KECK GRADUATE INSTITUTE   (United States)

Author keywords

Antisense; Gene therapy; Non viral vectors; Oncogenes; Phosphorothioate oligodeoxynucleotide (ODN); Ribozymes; Short interfering RNA (siRNA); Viral vectors

Indexed keywords

ALPHA INTEGRIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; CISPLATIN; CYCLIN D1; DACARBAZINE; EPSTEIN BARR VIRUS ANTIGEN; GELATINASE B; GROWTH FACTOR RECEPTOR; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; MESSENGER RNA; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; PROTEIN BCL 2; PROTEIN FOS; PROTEIN P21; PROTEIN P53; RECOMBINANT DNA; RIBOZYME; SMALL INTERFERING RNA; TELOMERASE; TRANSFERRIN; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; CATALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; GENE TARGETING; GENE TECHNOLOGY; GENE THERAPY; GENETIC MODEL; GENETIC STABILITY; GENOMICS; GLIOMA; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LYMPHOMA; MEDICAL RESEARCH; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CARCINOMA; RETINITIS; REVIEW; SOLID TUMOR; TELECOMMUNICATION; TUMOR GROWTH; VALIDATION PROCESS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE TARGETING; GENE THERAPY; HUMANS; MODELS, GENETIC; OLIGONUCLEOTIDES, ANTISENSE; RNA, CATALYTIC; RNA, MESSENGER; RNA, SMALL INTERFERING;

APUS APUS;

EID: 4844230625     PISSN: 13892010     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389201043376689     Document Type: Review

References (22)

1. Kashani-Sabet, M. and Scanlon, K.J. (2002) in The Cancer Handbook, London, England: Macmillan Publisher, Chapter 91, pp. 1439-1449
2. McManus, M. T. and Sharp, S. A. (2002). Nature Review Genetics, 3, 737-747.
3. Hutvagner, G. and Zamore, P. D. (2002). Current Opinion in Genetics & Development, 12(2), 225-232.
4. Zaug, A. J. and Cech, T. R. (1986) Science, 231, 470-475.
5. Haseloff, J. and Gerlach, W.L. (1988) Nature, 334, 585-591.
6. Herschlag, D. (1991) Proc. Natl. Acad. Sci. USA, 88, 6921-6925.
7. Symonds, R. H. (1992) Ann. Rev. Biochem., 61, 641-667.
8. Stein, C. and Cheng, Y. (1993) Science, 261, 1004-1012.
9. Zamecnik, P.C. and Stephenson, M.L. (1978) Proc. Natl. Acad. Sci. USA, 75, 280-284.
10. Stein, C. A. (2001) J. Clin. Invest., 108, 641-644.
11. Irie, A., Kijima, H., Ohkawa, T., Bouffard, D., Suzuki, T., Curcio, L., Holm, P., Sassani, A. and Scanlon, K.J. (1997) Adv. In Pharm., 40, 207-241.
12. Scanlon, K.J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J.J. and Kashani-Sabet, M. (1991). Proc. Natl. Acad. Sci. USA, 88, 10597-10595.
13. Scanlon, K.J., Ishida, H. and Kashani-Sabet, M. (1994) Proc. Natl. Acad. Sci. USA, 91, 11123-11127.
14. Scanlon, K.J. and Kashani-Sabet, M. (eds.), (1998) in Ribozymes in the Gene Therapy of Cancer. (R. G. Landes, Austin, TX).
15. Sarver, N., Cantin, E. M., Chang, P. S. and Rossi, J. J. (1990) Science, 247, 1222-1225.
16. McCaffrey, A. P., Nakai, H., Pandey, K., Huang, Z., Salazar, F. H., Xu, H., Wieland, S. F., Marion, P. L. and Kay, M. A. (2003) Biotechnology, 21, 639-644.
17. Dykxhoorn, D. M., Novina, C. D. and Sharp, P. A. (2003) Mol. Cell Biology, 4, 457-467.
18. Gottesman, M. (2003) Cancer Gene Therapy, 10, 501-508.
19. Kohn, D. B., Sadelain, M. and Glorioso, J. C. (2003) Nature Review; Cancer, 3, 477-487.
20. Kashani-Sabet M., Yong L. and Fong S. (2002) Proc. Natl. Acad. Sci. USA, 99, 3878-3883.
21. Kirchweger, G. (2002) Mol. Ther., 6, 301-302.
22. Lebedeva, I. and Stein, C. A. (2001) Annu. Rev. Pharmacol. Toxicol., 41, 403-419.